Filing Flows › Zevra Therapeutics (ZVRA) › Q1 2025
Zevra Therapeutics (ZVRA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Zevra Therapeutics (ZVRA) reported revenue of $20.4M for the first quarter 2025 (Q1 2025), +496% from a year earlier and +69% from the quarter before. Operating margin was -26.3%, net loss $3.1M (15.2% of revenue).
Zevra Therapeutics, Q1 2025: revenue $20.4M (+496% year over year), operating margin -26.3%, net loss $3.1M, operating cash flow −$8.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.4M | +69% | +496% |
| Operating profit | −$5.4M | — | — |
| Net earnings | −$3.1M | — | — |
| Operating cash flow | −$8.2M | — | — |
What changed
Revenue was $20.4M in Q1 2025, up 496% year over year and up 69% from the previous quarter.
Operating costs exceeded revenue by $5.4M, an operating margin of -26.3%. Total costs grew 8% against revenue growth of 496%. The fastest-growing cost line was Cost of revenue (+669%). The quarter ended with a net loss of $3.1M, narrower than the previous quarter's $35.7M loss. Non-operating items added $3.4M, -180% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$8.2M. Non-cash charges added back $1.6M of depreciation and amortization and $3.1M of share-based compensation. Working capital and other items used $9.9M. Capital expenditures of $99K exceeded it, leaving free cash flow of −$8.3M.
Questions
What was Zevra Therapeutics' revenue in the first quarter 2025?
Zevra Therapeutics (ZVRA) reported revenue of $20.4M for the first quarter 2025 (Q1 2025), +496% from a year earlier and +69% from the quarter before.
Was Zevra Therapeutics profitable in the first quarter 2025?
Operating loss was $5.4M (-26.3% of revenue) and net loss $3.1M.
Source: Zevra Therapeutics 10-Q on SEC EDGAR.